Contact
Please use this form to send email to PR contact of this press release:
Biomed Industries to Present Phase 2 Data on NA-931—an Oral Alternative to Injectables for Obesity—at ObesityWeek® 2025
TO:
Michael Willis
Biomed Industries, Inc.
+1 800-824-5135